These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24592948)

  • 21. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.
    Kunze D; Wuttig D; Kausch I; Blietz C; Blumhoff L; Burmeister Y; Kraemer K; Fuessel S; Toma M; Schwenzer B; Meye A; Grimm MO; Hakenberg OW; Jocham D; Wirth MP
    Int J Oncol; 2008 May; 32(5):1049-56. PubMed ID: 18425331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of oncogene expression by antisense nucleic acids.
    Hélène C
    Eur J Cancer; 1994; 30A(11):1721-6. PubMed ID: 7833151
    [No Abstract]   [Full Text] [Related]  

  • 23. Overview of target validation and the impact of oligonucleotides.
    Jones SW; Lindsay MA
    Curr Opin Mol Ther; 2004 Oct; 6(5):546-50. PubMed ID: 15537056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense oligonucleotides in cancer.
    Castanotto D; Stein CA
    Curr Opin Oncol; 2014 Nov; 26(6):584-9. PubMed ID: 25188471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI; Cheng K; Guntaka RV
    Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhibitory effect of silencing STAT3 gene with short hairpin RNA mediated by polyamidoamine dendrimers on growth of prostate cancer].
    Zhao WM; Xiu YC; Xu Y; Wang YM; Cheng ZK; Yu Q; Kong DL
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):575-9. PubMed ID: 18210874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical development of antisense oligonucleotides as anti-cancer therapeutics.
    Chen HX
    Methods Mol Med; 2003; 75():621-36. PubMed ID: 12407768
    [No Abstract]   [Full Text] [Related]  

  • 28. Better blocker: RNA interference dazzles research community.
    Garber K
    J Natl Cancer Inst; 2003 Apr; 95(7):500-2. PubMed ID: 12671010
    [No Abstract]   [Full Text] [Related]  

  • 29. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs.
    Zhang YC; Taylor MM; Samson WK; Phillips MI
    Methods Mol Med; 2005; 106():11-34. PubMed ID: 15375310
    [No Abstract]   [Full Text] [Related]  

  • 30. The use of gene therapy in cancer research and treatment.
    Shinohara ET; Lu B; Hallahan DE
    Technol Cancer Res Treat; 2004 Oct; 3(5):479-90. PubMed ID: 15453813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA interference advances to early-stage clinical trials.
    Brower V
    J Natl Cancer Inst; 2010 Oct; 102(19):1459-61. PubMed ID: 20870977
    [No Abstract]   [Full Text] [Related]  

  • 32. Stat3 as a potential target for cancer immunotherapy.
    Kortylewski M; Yu H
    J Immunother; 2007; 30(2):131-9. PubMed ID: 17471161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanosize delivery as an emerging platform for cancer therapy.
    Li CQ; Zhang GX
    Cancer Biol Ther; 2008 Nov; 7(11):1860-2. PubMed ID: 19151586
    [No Abstract]   [Full Text] [Related]  

  • 34. STAT3 interacts with Skp2/p27/p21 pathway to regulate the motility and invasion of gastric cancer cells.
    Wei Z; Jiang X; Qiao H; Zhai B; Zhang L; Zhang Q; Wu Y; Jiang H; Sun X
    Cell Signal; 2013 Apr; 25(4):931-8. PubMed ID: 23333463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
    Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
    Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA interference--a silent but an efficient therapeutic tool.
    Ramachandran PV; Ignacimuthu S
    Appl Biochem Biotechnol; 2013 Mar; 169(6):1774-89. PubMed ID: 23340870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.
    Aggarwal BB; Sethi G; Ahn KS; Sandur SK; Pandey MK; Kunnumakkara AB; Sung B; Ichikawa H
    Ann N Y Acad Sci; 2006 Dec; 1091():151-69. PubMed ID: 17341611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death.
    Borghouts C; Tittmann H; Delis N; Kirchenbauer M; Brill B; Groner B
    Mol Cancer Res; 2010 Apr; 8(4):539-53. PubMed ID: 20371673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligonucleotides as modulators of cancer gene expression.
    Curcio LD; Bouffard DY; Scanlon KJ
    Pharmacol Ther; 1997; 74(3):317-32. PubMed ID: 9352587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular dynamics simulation and binding energy calculation for estimation of oligonucleotide duplex thermostability in RNA-based therapeutics.
    Shen L; Johnson TL; Clugston S; Huang H; Butenhof KJ; Stanton RV
    J Chem Inf Model; 2011 Aug; 51(8):1957-65. PubMed ID: 21702481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.